Clinical profile and cardiovascular events in patients with atrial fibrillation and hematologic malignancies with recent initiation of targeted therapy: Real-life data from CANAC-FA registry

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Problems in Cardiology Pub Date : 2024-12-18 DOI:10.1016/j.cpcardiol.2024.102974

Alberto Piserra López-Fernández De Heredia , Martín Ruiz Ortiz , Javier Torres Llergo , Magdalena Carrillo Bailen , María Sánchez De Castro , Margarita Fernández De La Mata , Arancha Díaz Exposito , Alejandro I. Pérez Cabeza , Mónica Delgado Ortega , María García Fortes , Inmaculada Fernández Valenzuela , Marinela Chaparro Muñoz , Alicia Rodríguez Fernández , Ana María Rodríguez Almodóvar , Inara Alarcón De La Lastra Cubiles , Fátima Esteban Martínez , Francisco Javier Capote Huelva , José Javier Sánchez Fernandez , Dolores Mesa Rubio , Working Groups on Atrial Fibrillation and Cardio-Onco-Hematology of the Andalusian Society of Cardiology

{"title":"Clinical profile and cardiovascular events in patients with atrial fibrillation and hematologic malignancies with recent initiation of targeted therapy: Real-life data from CANAC-FA registry","authors":"Alberto Piserra López-Fernández De Heredia , Martín Ruiz Ortiz , Javier Torres Llergo , Magdalena Carrillo Bailen , María Sánchez De Castro , Margarita Fernández De La Mata , Arancha Díaz Exposito , Alejandro I. Pérez Cabeza , Mónica Delgado Ortega , María García Fortes , Inmaculada Fernández Valenzuela , Marinela Chaparro Muñoz , Alicia Rodríguez Fernández , Ana María Rodríguez Almodóvar , Inara Alarcón De La Lastra Cubiles , Fátima Esteban Martínez , Francisco Javier Capote Huelva , José Javier Sánchez Fernandez , Dolores Mesa Rubio , Working Groups on Atrial Fibrillation and Cardio-Onco-Hematology of the Andalusian Society of Cardiology","doi":"10.1016/j.cpcardiol.2024.102974","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>\"Real-life\" data on cardiovascular management and clinical outcomes in patients with atrial fibrillation (AF) and hematologic malignancies are limited.</div></div><div><h3>Aim</h3><div>To describe the clinical profile and incidence of cardiovascular events in this population.</div></div><div><h3>Methods</h3><div>Data were obtained from the CANAC-FA Registry, an observational, multicenter and retrospective study. A review of the medical records of patients who had consulted for chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) between 2017 and 2019 was conducted in five hospitals in Spain. Patients with atrial fibrillation (AF) were identified, and the initial visit during which specific treatment for the neoplasm was administered was considered the baseline visit. The follow-up period concluded in 2021. Events of interest included major bleeding, cardiovascular events (hospital admission for cardiovascular causes or cardiovascular death), and death from any cause.</div></div><div><h3>Results</h3><div>A total of 7,793 patients were reviewed, of whom 1,189 (15%) had AF and 81 (1%) had AF and had initiated a specific hematological treatment within the previous year. Of these patients, 48 (59%) had MM and 33 (41%) had CLL. The mean values for the Charlson, CHA2DS2-VASc and HAS-BLED indices were 5.3 ± 1.7, 3.4 ± 1.5 and 2.4 ± 1.1, respectively. Anticoagulants were prescribed to 85% of patients, with a majority (42%) receiving direct anticoagulants. After a maximum follow-up period of 59 months, the incidences of events at 1, 2 and 3 years of follow-up were: 1.2±1.2%, 1.2±1.2 and 3.5±2.5% for major bleeding; 11.6±3.7%, 11.6±3.7 and 17.2±5.3% for cardiovascular events; and 27.6±5.0%, 41.5±6.3 and 51.3±6.9% for all-cause mortality.</div></div><div><h3>Conclusions</h3><div>The incidence of cardiovascular events was high in this population, suggesting the need to implement more effective preventive strategies.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 3","pages":"Article 102974"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0146280624006091","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

"Real-life" data on cardiovascular management and clinical outcomes in patients with atrial fibrillation (AF) and hematologic malignancies are limited.

Aim

To describe the clinical profile and incidence of cardiovascular events in this population.

Methods

Data were obtained from the CANAC-FA Registry, an observational, multicenter and retrospective study. A review of the medical records of patients who had consulted for chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) between 2017 and 2019 was conducted in five hospitals in Spain. Patients with atrial fibrillation (AF) were identified, and the initial visit during which specific treatment for the neoplasm was administered was considered the baseline visit. The follow-up period concluded in 2021. Events of interest included major bleeding, cardiovascular events (hospital admission for cardiovascular causes or cardiovascular death), and death from any cause.

Results

A total of 7,793 patients were reviewed, of whom 1,189 (15%) had AF and 81 (1%) had AF and had initiated a specific hematological treatment within the previous year. Of these patients, 48 (59%) had MM and 33 (41%) had CLL. The mean values for the Charlson, CHA2DS2-VASc and HAS-BLED indices were 5.3 ± 1.7, 3.4 ± 1.5 and 2.4 ± 1.1, respectively. Anticoagulants were prescribed to 85% of patients, with a majority (42%) receiving direct anticoagulants. After a maximum follow-up period of 59 months, the incidences of events at 1, 2 and 3 years of follow-up were: 1.2±1.2%, 1.2±1.2 and 3.5±2.5% for major bleeding; 11.6±3.7%, 11.6±3.7 and 17.2±5.3% for cardiovascular events; and 27.6±5.0%, 41.5±6.3 and 51.3±6.9% for all-cause mortality.

Conclusions

The incidence of cardiovascular events was high in this population, suggesting the need to implement more effective preventive strategies.

查看原文本刊更多论文

最近开始靶向治疗的房颤和血液恶性肿瘤患者的临床概况和心血管事件：来自CANAC-FA登记的真实数据

背景：房颤（AF）和血液恶性肿瘤患者心血管管理和临床结果的“现实生活”数据是有限的。目的：描述该人群的临床概况和心血管事件发生率。方法：数据来自CANAC-FA Registry，这是一项观察性、多中心、回顾性研究。在西班牙的五家医院对2017年至2019年间就诊的慢性淋巴细胞白血病（CLL）或多发性骨髓瘤（MM）患者的医疗记录进行了回顾。确定心房颤动（AF）患者，并在对肿瘤进行特异性治疗的首次就诊期间被认为是基线就诊。后续阶段于2021年结束。我们关注的事件包括大出血、心血管事件（因心血管原因住院或心血管死亡）和任何原因导致的死亡。结果：共回顾了7793例患者，其中1189例（15%）患有房颤，81例（1%）患有房颤并在前一年内开始了特定的血液治疗。在这些患者中，48例（59%）患有MM， 33例（41%）患有CLL。Charlson、CHA2DS2-VASc和ha - bled指数的平均值分别为5.3±1.7、3.4±1.5和2.4±1.1。85%的患者使用抗凝剂，大多数（42%）患者直接使用抗凝剂。最长随访59个月后，1年、2年和3年的事件发生率分别为：大出血的发生率分别为1.2±1.2%、1.2±1.2和3.5±2.5%；心血管事件发生率分别为11.6±3.7%、11.6±3.7和17.2±5.3%；全因死亡率分别为27.6±5.0%、41.5±6.3和51.3±6.9%。结论：该人群心血管事件发生率较高，提示需要实施更有效的预防策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Problems in Cardiology 医学-心血管系统

CiteScore

4.80

自引率

2.40%

发文量

392

审稿时长

6 days

期刊介绍： Under the editorial leadership of noted cardiologist Dr. Hector O. Ventura, Current Problems in Cardiology provides focused, comprehensive coverage of important clinical topics in cardiology. Each monthly issues, addresses a selected clinical problem or condition, including pathophysiology, invasive and noninvasive diagnosis, drug therapy, surgical management, and rehabilitation; or explores the clinical applications of a diagnostic modality or a particular category of drugs. Critical commentary from the distinguished editorial board accompanies each monograph, providing readers with additional insights. An extensive bibliography in each issue saves hours of library research.